Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of OsrhAAT in Healthy Volunteers
NCT05315921Phase 1Unknown
- Sponsor
- Wuhan Healthgen Biotechnology Corp.
- Start
- Mar 2022
- Primary completion
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of alpha-1-proteinase inhibitor in alpha-1 antitrypsin deficiency (AATD) (6 arms), sponsored by Wuhan Healthgen Biotechnology Corp. Primary endpoint: Incidence of adverse events (AEs), serious adverse events (SAEs), and infusion site reactions up to 180 days. Status: unknown.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT05315921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05315921.